Related Experiment Video
Updated: Jan 23, 2026
09:43
Transplantation of Zebrafish Pediatric Brain Tumors into Immune-competent Hosts for Long-term Study of Tumor Cell Behavior and Drug Response
Published on: May 17, 2017
12.1K
Towards Immunotherapy for Pediatric Brain Tumors
Stacie Shiqi Wang1, Pratiti Bandopadhayay2, Misty Rayna Jenkins3
1Immunology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Murdoch Children's Research Institute, Parkville, VIC 3052, Australia.
Trends in Immunology
|June 24, 2019
Summary
Immunotherapy offers new hope for treating pediatric brain tumors, especially high-grade glioma (HGG). Overcoming challenges in the developing brain and its immune system is key to successful treatment.
Area of Science:
- Pediatric Neuro-oncology
- Cancer Immunology
- Developmental Neuroscience
Background:
- Pediatric brain tumors are a leading cause of cancer-related death in children.
- Immunotherapy represents a significant advancement in cancer treatment, often termed the 'fourth pillar'.
- Applying immunotherapy to pediatric brain tumors, particularly high-grade glioma (HGG), presents unique challenges due to the developing central nervous system.
Purpose of the Study:
- To review current perspectives on immunotherapy for pediatric brain tumors.
- To focus on the application of immunotherapy in pediatric high-grade glioma (HGG).
- To highlight the specific challenges of immunotherapy in the context of the pediatric brain and its immune system.
Main Methods:
- Review of existing literature on immunotherapy strategies for pediatric brain tumors.
- Focus on Chimeric Antigen Receptor T cell (CAR-T) therapy, vaccine therapy, and checkpoint inhibition.
- Analysis of the unique biological and immunological factors of the pediatric brain.
Main Results:
- Immunotherapy, including CAR-T cell therapy, vaccines, and checkpoint inhibitors, shows promise for pediatric brain tumors.
- Understanding the intricacies of the developing brain and its immune system is crucial for therapeutic success.
- Significant tissue-specific challenges must be addressed for effective immunotherapy application.
Conclusions:
- Successful immunotherapy for pediatric brain tumors, especially HGG, requires a deep understanding of neurodevelopment and pediatric neuro-immunology.
- Overcoming challenges related to the pediatric central nervous system is essential for improving outcomes.
- Further research into tailored immunotherapy approaches is warranted for this vulnerable population.
Related Concept Videos
01:27Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
214
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
271
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
271
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
199
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
199
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
260
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
260
02:07Tumor Progression
7.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.3K